Lunai Bioworks Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lunai Bioworks Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 4.5 times its market value (net debt). Lower than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $26 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 96% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-0.8×Operating cash was negative last year, while some debt falls due within a year.
Higher than 67% of Healthcare companies in United States.
Cash Cushion Ratio
4.5× debtDebt, after subtracting cash, is 4.5 times its market value (net debt).
Lower than almost all Healthcare companies in United States.
Tangible Assets Ratio
26%Of every $100 the company owns, $26 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 96% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Lunai Bioworks Inc. made a loss over the last year. Lunai Bioworks Inc. owes $1.97 for every $1 it owns. Lunai Bioworks Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Jun 2025.
P/E ratio
LossLunai Bioworks Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.22Lunai Bioworks Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$2 MThe total market value of all of Lunai Bioworks Inc.'s shares at today's price (share price × number of shares), smaller than 98% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
NegativeLunai Bioworks Inc.'s net worth is negative ($10 M below zero, balance sheet 31 Mar 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.97×Lunai Bioworks Inc. owes $1.97 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Dividend yield
NoneLunai Bioworks Inc. does not currently pay a dividend.
Profit growth
LossLunai Bioworks Inc. made a loss in each of the last two years.
Interest cover
Not coveredLunai Bioworks Inc.'s operating profit did not cover its interest costs in the year to Jun 2025.
Cash vs debt
Net debtLunai Bioworks Inc. had $10 M more debt than cash (net debt) at Jun 2025.
Questions
How much does Lunai Bioworks Inc. owe compared with what it owns?
Lunai Bioworks Inc. owes $1.97 for every $1 it owns, so it owes more than it owns, higher than 96% of Healthcare companies in United States.
Does Lunai Bioworks Inc. pay a dividend?
No. Lunai Bioworks Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.